Risk assessment of toxaphene and its breakdown products: Time for a change?

Critical Reviews in Toxicology

Volumn 38, Issue 9, 2008, Pages 805-815

  Lamb IV, James C ^a   Neal, Barbara H ^a   Goodman, Jay I ^b  

^a The Weinberg Group   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPHECLOR;

CARCINOGENICITY; GAP JUNCTION; KIDNEY TUMOR; LIVER TUMOR; MUTAGENICITY; REVIEW; RISK ASSESSMENT; SYNTHESIS;

ANIMALS; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; HUMANS; INSECTICIDES; MUTAGENICITY TESTS; PESTICIDE RESIDUES; RISK ASSESSMENT; TOXAPHENE;

RATTUS;

EID: 54349094066     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.1080/10408440802237698     Document Type: Review

References (50)

1. Agency for Toxic Substances and Disease Registry. (1996). Toxicological profile for toxaphene. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service.
2. Bartos, T., Skarek, M., Cupr, P., Kosubova, P., and Holoubek, I. (2005). Genotoxic activity of a technical toxaphene mixture and its photodegradation products in SOS genotoxicity tests. Mutation Res. 565:113-120.
3. Battershill, J.M., and Fielder, R.J. (1998). Mouse-specific carcinogens: An assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice. Hum. Exp. Toxicol. 17:193-205.
4. Besselink, H.T., Nixon, E., McHugh, B., Klungsøyr, J., and Brouwer, A. (2000). In vitro and in vivo tumor promoting potency of technical toxaphene, UV-irradiated toxaphene, and biotransformed toxaphene. Organohalogen Compounds 47:113-116.
5. Borghoff, S.J., Short, B.G., and Swenberg, J.A. (1990). Biochemical mechanisms and pathobiology of α2u-globulin nephropathy. Annu. Rev. Pharmacol. Toxicol. 30:349-367.
6. Breña-Valle, M., and Serment-Guerrero J. (1998). SOS induction by gamma-radiation in Escherichia coli strains defective in repair and/or recombination mechanisms. Mutagensis. 13(6):637-641.
7. Carmichael, N.G., Enzmann, H., Pate, I., and Waechter, F. (1997). The significance of mouse liver tumor formation for carcinogenic risk assessment: Results and conclusions from a survey of ten years of testing by the agrochemical industry. Environ. Health Perspect. 105:1196-1203.
8. Coelhan, M., and Parlar, H. (1996). The nomenclature of chlorinated bornanes and camphenes relevant to toxaphene. Chemosphere 32:217-228.
9. de Geus, H.-J., Besselink, H., Brouwer, A., Klungsøyr, J., McHugh, B., Nixon, E., Rimkus, G.G., Wester, P.G., and de Boer, J. (1999). Environmental occurrence, analysis, and toxicology of toxaphene compounds. Environ. Health Perspect. 107(Suppl. 1):115-144.
10. Fitzgerald, D.J., and Yamasaki, H. (1990). Tumor promotion: Models and assay systems. Teratogen. Carcinogen. Mutagen. 10:89-102.
11. Geyer, H.J., Kaune, A., Schramm, K.W., Rimkus, G., Scheunert, I., Bruggemann, R., Altschuh, J., Steinberg, C.E., Vetter, W., Kettrup, A., and Muir, D.C. (1999). Predicting bioconcentration factors (BCFs) of polychlorinated bornane (toxaphene) congeners in fish and comparison with bioaccumulation factors (BAFs) in biota from the aquatic environment. Chemosphere 39:655-663.
12. Goodman, J.I., Brusick, D.J., Busey, W.M., Cohen, S.M., Lamb, J.C., and Starr, T.B. (2000). Reevaluation of the cancer potency factor of toxaphene: Recommendations from a peer review panel. Toxicol Sci. 55:3-16.
13. Goodman, J.I. (1998). The traditional toxicologic paradigm is correct: Dose influences mechanism. Environ. Health Perspect. 106(Suppl. 1):285-288.
14. Goodman, J.I., and Watson, R.E. (2002). Altered DNA methylation: A secondary mechanism involved in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 42:501-525.
15. Hard, G.C., Rodgers, I.S., Baetcke, K.P., Richards, W.L., McGaughy, R.E., and Valcovic, L.R. (1993). Hazard evaluation of chemicals that cause accumulation of α2u-globulin, hyaline droplet nephropathy, and tubule neoplasia in the kidneys of male rats. Environ. Health Perspect. 99:313-349.
16. Hedli, C.C., Snyder, R., Kinoshita, F.K., and Steinberg, M. (1998). Investigation of hepatic cytochrome P-450 enzyme induction and DNA adduct formation in male CD/1 mice following oral administration of toxaphene. J. Appl. Toxicol. 18:173-178.
17. Hill, R.N., Crisp, T.M., Hurley, P.M., Rosenthal, S.L., and Singh, D.V. (1998). Assessment of Thyroid Follicular Cell Tumors. U.S. Environmental Protection Agency, Risk Assessment Forum, Washington, DC.
18. Holsapple, M.P., Pitot, H.C., Cohen, S.M., Boobis, A.R., Klaunig, J.E., Pastoor, T., Dellarco, V.L., and Dragan, Y.P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 89:51-56.
19. Jahnke, G.D., Choksi, N.Y., Moore, J.A., and Shelby, M.D. (2004). Thyroid toxicants: Assessing reproductive health effects. Environ. Health Perspect. 112:363-368.
20. Kamendulis, L.M., Isenberg, J.S., Smith, J.H., Pugh, G., Jr., Lington, A.W., and Klaunig, J.E. (2002). Comparative effects of phthalate monoesters on gap junctional intercellular communication and peroxisome proliferation in rodent and primate hepatocytes. J. Toxicol. Environ. Health A 65:569-588.
21. Kang, K.S., Wilson, M.R., Hayashi, T., Chang, C.C., and Trosko, J.E. (1996). Inhibition of gap junctional intercellular communication in normal human breast epithelial cells after treatment with pesticides, PCBs, and PBBs, alone or in mixtures. Environ. Health Perspect. 104:192-200.
22. Korytar, P., van Stee, L.L., Leonards, P.E., de Boer, J., and Brinkman, U.A. (2003). Attempt to unravel the composition of toxaphene by comprehensive two-dimensional gas chromatography with selective detection. J. Chromatogr. A 994:179-189.
23. Lehman-McKeeman, L.D., Rivera-Torres, M.I., and Caudill, D. (1990). Lysosomal degradation of alpha 2u-globulin and alpha 2u-globulinxenobiotic conjugates. Toxicol. Appl. Pharmacol. 103:539-548.
24. Leonards, P.E., Besselink, H., Brouwer, A., McHugh, B., Nixon, E., Rimkus, G., and de Boer, J. (2006). Toxicological risks to humans of toxaphene residues in fish. Organohalogen Compounds 68:1414-1417.
25. Litton Bionetics. (1978). Carcinogenic Evaluation in Mice: Toxaphene. Final Report. Prepared by Litton Bionetics, Inc. Kensington, MD, for Hercules, Inc., Wilmington, DE. LBI Project 20602.
26. Litton Bionetics. (1979). Evaluation of Carcinogenic Potential in Hamsters: Toxaphene. Final Report. Prepared by Litton Bionetics, Inc., Kensington, MD, for Hercules, Inc., Wilmington, DE. LBI Project 20601.
27. Maruya, K.A., Wakeham, S.G., Vetter, W., and Francendese, L. (2000). Prominent chlorobornane residues in estuarine sediments contaminated with toxaphene. Environ. Toxicol. Chem. 19:2198-2203.
28. MATT. (2000). Investigation into the Monitoring, Analysis and Toxicity of Toxaphene in Marine Foodstuffs. Final Report: FAIR CT PL.96.3131. European Union, Brussels.
29. Meek, M.E., Bucher, J.R., Cohen, S.M., Dellarco, V., Hill, R.N., Lehman-McKeeman, L.D., Longfellow, D.G., Pastoor, T., Seed, J., and Patton, D.E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33:591-653.
30. National Cancer Institute. (1979). Bioassay of Toxaphene for Possible Carcinogenicity. Carcinogenesis Testing Program, Division of Cancer Cause and Prevention, NCI, National Institute of Health, Bethesda, MD. U.S. Department of Health, Education and Welfare. DHEW Publication No. (NIH) 79-837.
31. National Toxicology Program. (2005). Report on Carcinogens, 11th ed. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, Washington, DC.
32. Quillardet P., Huisman O., D'Ari, R., and Hofnung, M. (1982). The SOS chromotest: Direct assay of the expression of gene sfiA as a measure of genotoxicity of chemicals. Biochimie. 64(8-9):797-801.
33. Ritter, L., Totman, C., Krishnan, K., Carrier, R., V́ezina, A., and Morisset, V. (2007). Deriving uncertainty factors for threshold chemical contaminants in drinkingwater. J. Toxicol. Environ. Health B 10:527-557.
34. Saleh, M.A. (1991). Toxaphene: Chemistry, biochemistry, toxicity and environmental fate. Rev. Environ. Contam. Toxicol. 118:1-85.
35. Schrader, T.J., Boyes, B.G., Matula, T.I., Heroux-Metcalf, C., Langlois, I., and Downie, R.H. (1998). In vitro investigation of toxaphene genotoxicity in S. typhimurium and Chinese hamster V79 lung fibroblasts. Mutat. Res. 413:159-168.
36. Simon, T., and Manning, R. (2006). Development of a reference dose for the persistent congeners of weathered toxaphene based on in vivo and in vitro effects related to tumor promotion. Regul. Toxicol. Pharmacol. 44:268-281.
37. Steinberg, M., Kinoshita, F.K., and Ballantyne, M. (1998). Mutagenicity studies with toxaphene congeners. Organohalogen Compounds 35:243-246.
38. Swenberg, J.A., and Lehman-McKeeman, L. D. (1999). α2-Urinary globulin-associated nephropathy as a mechanism of renal tubule cell carcinogenesis in male rats. In: Species Differences in Thyroid, Kidney, and Urinary Bladder Carcinogenesis, C.C. Capen, E. Dybing, J.M. Rice, and J.D. Wilbourn, eds., pp. 95-118. IARC Scientific Publication No. 147. IARC, Lyon, France.
39. Trosko, J.E., Jone, C., and Chang, C.C. (1987). Inhibition of gap junctional-mediated intercellular communication in vitro by aldrin, dieldrin, and toxaphene: A possible cellular mechanism for their tumor-promoting and neurotoxic effects. Mol. Toxicol. 1:83-93.
40. Trosko, J.E., and Ruch, R.J. (1998). Cell-cell communication in carcinogenesis. Front. Biosci. 3:d208-36.
41. Tsuda, H., Fukushima, S., Wanibuchi, H., Morimura, K., Nakae, D., Imaida, K., Tatematsu, M., Hirose, M., Wakabayashi, K., and Moore, M.A. (2003). Value of GST-P positive preneoplastic hepatic foci in dose-response studies of hepatocarcinogenesis: Evidence for practical thresholds with both genotoxic and nongenotoxic carcinogens. A review of recent work. Toxicol. Pathol. 31:80-86.
42. University of California Berkeley Laboratory. (2007). The Carcinogenic Potency Database (CPDB). http://potency.berkeley.edu
43. U.S. Environmental Protection Agency. (1986). Guidelines for Carcinogen Risk Assessment. U.S. Environmental Protection Agency: Washington, DC.
44. U.S. Environmental Protection Agency. (1991). Alpha-u2-globulin: Association With Chemically Induced Renal Toxicity and Neoplasia in the Male Rat. U.S. EPA/625/3-91/019F. Washington, DC.
45. U.S. Environmental Protection Agency. (2005). Guidelines for Carcinogen Risk Assessment. U.S. Environmental Protection Agency, Washington, DC.
46. U.S. Environmental Protection Agency Integrated Risk Information System. (1991). Toxaphene. http://www.epa.gov/iris/subst/0346.htm.
47. Vetter, W., and Kirchberg, D. (2001). Production of toxaphene enantiomers by enantioselective HPLC after isolation of the compounds from an anaerobically degraded technical mixture. Environ. Sci. Technol. 35(5):960-965.
48. Waritz, R.S., Steinberg, M., Kinoshita F., Kelly C.M., and Richter W. (1996). Thyroid function and thyroid tumors in toxaphene-treated rats. Regul. Toxicol. Pharmacol. 24:184-192.
49. Whysner, J., Ross, P.M., and Williams, G.M. (1996). Phenobarbital mechanistic data and risk assessment: Enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71:153-191.
50. Young, J.C., and Freeman, A. D. (2004). Comparing the Mutagenicity of Toxaphene after aging in Anoxic Soils and Accumulating in Fish. Final report for projects R9C-R570-NASA and 1CR234-NASA with the Office of Research and Development of the U.S. Environmental Protection Agency, Cincinnati, OH.